Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies

• Published in: EBioMedicine Vol. 69; p. 103427
• Main Authors: Lopez-Santalla, Mercedes, Bueren, Juan A., Garin, Marina I.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.07.2021; Elsevier
• Subjects: Animal models; Improvements in MSC-based therapy; Mesenchymal stem/stromal cells; Protocols; Review; Rheumatoid arthritis; PP; Protocols; RANKL; TRAF; IHC; RANTES; MHC; Consec; MPO; MensMSCs; COMP; PPAR; Tfh; IA; iLNs; O-MSCs; HLA-II; ID; AD; IL; IM; IN; IP; IAA; FOXP3; IV; RA; Gilz; MPs; P-MSCs; AS; AT; RF; AAV; miR; ISCT; OVA; AD-MSCs; <; =; Ig; >; CFA; H/E; A; Animal models; SVF; D; Flk; sIL6R; MRI; F; SF-MSCs; G; BM; M; P; SC; Tr1; OVAIA; rAIA; S; SF; SNP; MPCs; KC; X; TGF-β; SM; SO; SP; CD; GSH-Px; dLNs; DAB; ESR; Tregs; SOD; T-AOC; CM; PGIA; RAGE; BMZ; TF; Bregs; T-MSCs; MTC; sCIA; ETN; Mesenchymal stem/stromal cells; HMGB-1; ILA; LP; ALP; MIP-2; OPG; DM; PTPN22; MDA; UC; Mtx; NF-κB; IFN-γ; MSCs; Th; IDO; mLNs; EMA; CTLA4; iNOS; CIA; TBO; CII; IL-1RA; IP10; BM-MSCs; SIRT1; GIP; AxLNs; mBSA; MMP; SAA; NA; ANA; Rheumatoid arthritis; G-MSCs; NK; mAIA; CRP; GITR; NRP-1; APCP; MCP-1; TCR; Tol-DCs; IFA; DMARDs; IFI; ERDF; HDL; OCPs; DCs; LDL; CXCR3; Exos; NSAIDs; SSEA; GSH; rCIA; WT; RORγT; SM-MSCs; TNFR; EVs; GLP-1; µCT; VEGF; STAT3; CAIA; AhR; Bzb; MVs; PBMCs; PA; UC-MSCs; PB; PLGA; TNF-α; pLNs; TRACP; PG; HSCs; Improvements in MSC-based therapy; NuMa
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2021.103427

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction and is a primary cause of disability worldwide. Despite the existence of numerous anti-rheumatic drugs, a significant number of patients with RA do not respond or are intolerant to current treatments. Mesenchymal stem/stromal cell (MSCs) therapy represents a promising therapeutic tool to treat RA, mainly attributable to the immunomodulatory effects of these cells. This review comprises a comprehensive analysis of the scientific literature related to preclinical studies of MSC-based therapy in RA to analyse key aspects of current protocols as well as novel approaches which aim to improve the efficacy of MSC-based therapy.